Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy

MLA

Pierpaolo, Di Micco, et al. “Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy.” Life; Volume 12; Issue 8; Pages: 1128, July 2022. EBSCOhost, https://doi.org/10.3390/life12081128.

APA

Pierpaolo, D. M., Vladimir Rosa, S., Carmen Fernandez, C., Francesco, D., Covadonga Gomez, C., Jose Luis Fernandez, T., Jose Antonio, P., Angeles, F., Elvira, G., Manuel Lopez, M., Manuel, M., & The Riete Investigators. (2022). Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy. Life; Volume 12; Issue 8; Pages: 1128. https://doi.org/10.3390/life12081128

Chicago

Pierpaolo, Di Micco, Salazar Vladimir Rosa, Capitan Carmen Fernandez, Dentali Francesco, Cuervo Covadonga Gomez, Torres Jose Luis Fernandez, Porras Jose Antonio, et al. 2022. “Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy.” Life; Volume 12; Issue 8; Pages: 1128, July. doi:10.3390/life12081128.